profit from every $100 of sales.
$0$100
Amylyx Pharmaceuticals
$31.80+2.88% today
+150.6% in 1 year
1-year low $11.381-year high $39.66
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Amylyx Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $22.2 million in 2022 to $0 in 2025, with -$145 million of profit last year.
SalesProfit
Amylyx Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Amylyx Pharmaceuticals | No profit yet | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Amylyx Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 22 | 381 | 87 | 0 | |
| 19 | 355 | -37 | 0 | |
| -201 | 39 | -256 | -153 | |
| -201 | 40 | -255 | -153 | |
| -198 | 49 | -302 | -145 | |
| -3.39 | 0.70 | -4.43 | -1.53 | |
| 86.5% | 93.3% | -42.6% | – | |
| -905.7% | 10.2% | -292.6% | – | |
| -892.4% | 12.9% | -345.4% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 391 | 517 | 194 | 333 |
| Cash | 63 | 170 | 77 | 227 |
| Total debt | 6 | 4 | 2 | 6 |
| Total liabilities | 51 | 84 | 29 | 27 |
| 341 | 433 | 165 | 305 | |
| 58 | 70 | 68 | 95 | |
| -45.9% | 7.0% | -121.1% | -38.9% | |
| -58.2% | 11.4% | -183.1% | -47.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -180 | 12 | -168 | -123 | |
| 3 | 1 | 0 | 0 | |
| -182 | 11 | -168 | -123 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 22 | 37 | 33 | 28 |
Valuation
- –
- –
- –
- 12.1×
- 46.8×
- –
- –
- -4.1%
- -7.4%
- 0.0%
Profitability
- -42.6%
- -292.6%
- -345.4%
- 0.0%
- -39.9%
- -51.0%
- -55.7%
- -51.1%
- -57.4%
- –
Growth
- +98.3%
- –
- +26.4%
- –
- +17.4%
Financial health
- -0.3×
- 0.02
- 1.9%
- –
- 14.27
- 17.85
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 11%of 958
Top 6%of 890
Bottom 20%of 987
What analysts expect
- Average price target
- $24.50
- Range
- $21.00 – $28.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.37 | -0.34 | −8.8% |
| Mar 3, 2026 | -0.30 | -0.31 | +3.2% |
| Nov 6, 2025 | -0.37 | -0.43 | +14.0% |
| Aug 7, 2025 | -0.46 | -0.44 | −4.5% |
| May 8, 2025 | -0.42 | -0.45 | +6.7% |
| Mar 4, 2025 | -0.55 | -0.49 | −12.2% |
| Nov 7, 2024 | -0.53 | -0.47 | −12.8% |
| Aug 8, 2024 | -0.73 | -0.38 | −92.1% |
News
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This WeekYahoo Finance · Aug 21, 2026Dow, S&P 500, Nasdaq Futures Slip As Global Bond Rout Catches Up With Markets: LUNR, MSTR, WYFI, AMLX Stocks In FocusYahoo Finance · Aug 19, 2026Why Amylyx Pharmaceuticals Stock Skyrocketed TodayYahoo Finance · Aug 18, 2026Amylyx surges on upcoming release of avexitide dataSeeking Alpha · Aug 17, 2026The newest story we have is from Aug 21, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
40No pass
Philip Fisher
37No pass
Peter Lynch
71Pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
33No pass
Questions about Amylyx Pharmaceuticals
Is Amylyx Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Amylyx Pharmaceuticals AI analysis
What does Amylyx Pharmaceuticals do?
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It is in Drug Manufacturers - Specialty & Generic.
Does Amylyx Pharmaceuticals pay a dividend?
No. Amylyx Pharmaceuticals does not pay a dividend at the moment.
Is Amylyx Pharmaceuticals stock halal?
Yes. Amylyx Pharmaceuticals passes our halal screen: its business is permitted and its debt is 0.1% of its market value, under the 30% limit. How we check
How has Amylyx Pharmaceuticals stock done over the past year?
Up 150.6% over the past twelve months, to $31.80. It traded between $11.38 and $39.66 and is 19.8% below its high.
Who are Amylyx Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Amylyx Pharmaceuticals's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.